Catherine Wadsworth

8.8k total citations · 1 hit paper
18 papers, 554 citations indexed

About

Catherine Wadsworth is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Catherine Wadsworth has authored 18 papers receiving a total of 554 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 4 papers in Surgery. Recurrent topics in Catherine Wadsworth's work include Cancer Immunotherapy and Biomarkers (15 papers), Lung Cancer Treatments and Mutations (10 papers) and Lung Cancer Diagnosis and Treatment (4 papers). Catherine Wadsworth is often cited by papers focused on Cancer Immunotherapy and Biomarkers (15 papers), Lung Cancer Treatments and Mutations (10 papers) and Lung Cancer Diagnosis and Treatment (4 papers). Catherine Wadsworth collaborates with scholars based in United States, United Kingdom and South Korea. Catherine Wadsworth's co-authors include Phillip A. Dennis, Corinne Faivre‐Finn, Shuji Murakami, Mustafa Özgüroğlu, Scott Antonia, Davey B. Daniel, Rina Hui, Augusto Villegas, Johan Vansteenkiste and Jhanelle E. Gray and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics and Annals of Oncology.

In The Last Decade

Catherine Wadsworth

17 papers receiving 547 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC

2019 305 citations Jhanelle E. Gray, Augusto Villegas et al. Journal of Thoracic Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Catherine Wadsworth United States	10	434	411	74	60	50	18	554
Nathan Comeaux United States	4	444 1.0×	308 0.7×	134 1.8×	62 1.0×	76 1.5×	9	559
Gastón Lucas Martinengo Japan	3	351 0.8×	414 1.0×	35 0.5×	58 1.0×	75 1.5×	6	524
Catherine Dubos‐Arvis France	8	310 0.7×	348 0.8×	27 0.4×	104 1.7×	36 0.7×	11	476
Junliang Cai United States	9	451 1.0×	397 1.0×	65 0.9×	29 0.5×	52 1.0×	12	534
Jahan Aghalar United States	5	269 0.6×	133 0.3×	98 1.3×	25 0.4×	66 1.3×	9	355
Ryan Assadi United States	4	245 0.6×	130 0.3×	44 0.6×	58 1.0×	40 0.8×	6	313
Kenji Nakahama Japan	11	451 1.0×	313 0.8×	50 0.7×	30 0.5×	51 1.0×	30	518
Sufia Safina Russia	9	272 0.6×	249 0.6×	40 0.5×	40 0.7×	51 1.0×	28	397
Angela White United States	6	287 0.7×	383 0.9×	36 0.5×	57 0.9×	17 0.3×	8	464
Oyeon Cho South Korea	12	202 0.5×	96 0.2×	40 0.5×	53 0.9×	107 2.1×	28	378

Countries citing papers authored by Catherine Wadsworth

Since Specialization

Citations

This map shows the geographic impact of Catherine Wadsworth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Catherine Wadsworth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Catherine Wadsworth more than expected).

Fields of papers citing papers by Catherine Wadsworth

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Catherine Wadsworth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Catherine Wadsworth. The network helps show where Catherine Wadsworth may publish in the future.

Co-authorship network of co-authors of Catherine Wadsworth

This figure shows the co-authorship network connecting the top 25 collaborators of Catherine Wadsworth. A scholar is included among the top collaborators of Catherine Wadsworth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Catherine Wadsworth. Catherine Wadsworth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Vansteenkiste, Johan, Jarushka Naidoo, Corinne Faivre‐Finn, et al.. (2024). Symptomatic Pneumonitis With Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC. JTO Clinical and Research Reports. 5(3). 100638–100638. 6 indexed citations

Garassino, Marina Chiara, Byoung Chul Cho, Joo-Hang Kim, et al.. (2020). Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study. Lung Cancer. 147. 137–142. 40 indexed citations

Faivre‐Finn, Corinne, David R. Spigel, Suresh Senan, et al.. (2020). Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC). Lung Cancer. 151. 30–38. 31 indexed citations

Gray, Jhanelle E., Augusto Villegas, Davey B. Daniel, et al.. (2019). Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC. Journal of Thoracic Oncology. 15(2). 288–293. 305 indexed citations breakdown →

Boothman, Anne-Marie, Marietta Scott, M. Ratcliffe, et al.. (2019). Impact of Patient Characteristics, Prior Therapy, and Sample Type on Tumor Cell Programmed Cell Death Ligand 1 Expression in Patients with Advanced NSCLC Screened for the ATLANTIC Study. Journal of Thoracic Oncology. 14(8). 1390–1399. 33 indexed citations

Gray, Jhanelle E., Augusto Villegas, Davey B. Daniel, et al.. (2019). Three-year overall survival update from the PACIFIC trial.. Journal of Clinical Oncology. 37(15_suppl). 8526–8526. 25 indexed citations

Vansteenkiste, Johan, Jarushka Naidoo, Corinne Faivre‐Finn, et al.. (2019). Efficacy of durvalumab in patients with stage III NSCLC who experience pneumonitis (PACIFIC). Annals of Oncology. 30. v592–v593. 12 indexed citations

Planchard, David, Byoung Chul Cho, Jhanelle E. Gray, et al.. (2019). First subsequent treatment after discontinuation of durvalumab in unresectable, stage III NSCLC patients from PACIFIC.. Journal of Clinical Oncology. 37(15_suppl). 9054–9054. 6 indexed citations

Planchard, David, Marina Chiara Garassino, L. Paz-Ares, et al.. (2019). Prevalence of programmed death ligand-1 (PD-L1) by demographic, disease and sample characteristics in unresectable, stage III NSCLC (PACIFIC). Annals of Oncology. 30. ii32–ii33. 1 indexed citations

10.

Garassino, Marina Chiara, Byoung Chul Cho, Julien Mazières, et al.. (2018). P1.01-21 Safety of Durvalumab Retreatment in Advanced NSCLC Patients Who Progressed Following Initial Disease Control In ATLANTIC. Journal of Thoracic Oncology. 13(10). S467–S468. 1 indexed citations

11.

Scott, Marietta, M. Ratcliffe, Catherine Wadsworth, et al.. (2018). MA19.02 Prior Therapy and Increased Expression of PD-L1 in NSCLC Tumor Samples. Journal of Thoracic Oncology. 13(10). S422–S422.

12.

Spigel, David R., Johan Vansteenkiste, Martin Reck, et al.. (2018). P1.16-05 Effect of Induction Chemotherapy in the PACIFIC Study. Journal of Thoracic Oncology. 13(10). S629–S629. 1 indexed citations

13.

Vansteenkiste, Johan, Jarushka Naidoo, Corinne Faivre‐Finn, et al.. (2018). MA05.02 PACIFIC Subgroup Analysis: Pneumonitis in Stage III, Unresectable NSCLC Patients Treated with Durvalumab vs. Placebo After CRT. Journal of Thoracic Oncology. 13(10). S370–S371. 30 indexed citations

14.

Raben, David, Corinne Faivre‐Finn, David R. Spigel, et al.. (2018). PACIFIC: Overall Survival with Durvalumab versus Placebo after Chemoradiotherapy in Stage III NSCLC. International Journal of Radiation Oncology*Biology*Physics. 102(5). 1607–1608. 2 indexed citations

15.

Garassino, Marina Chiara, Byoung Chul Cho, Joo-Hang Kim, et al.. (2018). Durvalumab in ≥ 3rd-line advanced NSCLC: Updated results from the phase 2 ATLANTIC study.. Journal of Clinical Oncology. 36(15_suppl). 9058–9058. 3 indexed citations

16.

Faivre‐Finn, Corinne, David R. Spigel, Suresh Senan, et al.. (2018). Efficacy and safety evaluation based on time from completion of radiotherapy to randomization with durvalumab or placebo in pts from PACIFIC. Annals of Oncology. 29. viii488–viii488. 23 indexed citations

17.

Garassino, Marina Chiara, Jhanelle E. Gray, Julien Mazières, et al.. (2017). Durvalumab in ≥ 3rd-line EGFR mutant/ALK+, locally advanced or metastatic NSCLC: Results from the phase 2 ATLANTIC study. Annals of Oncology. 28. ii28–ii29. 12 indexed citations

18.

Garassino, Marina Chiara, Johan Vansteenkiste, Joo-Hang Kim, et al.. (2017). PL04a.03: Durvalumab in ≥3rd-Line Locally Advanced or Metastatic, EGFR/ALK Wild-Type NSCLC: Results from the Phase 2 ATLANTIC Study. Journal of Thoracic Oncology. 12(1). S10–S11. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact